First Berlin Equity Research ends coverage of Marinomed Biotech
Bitget2026/09/24 15:08- First Berlin ended analyst coverage of Marinomed Biotech on Sept. 24, citing the company’s insolvency-driven shutdown.
- Marinomed sought court-administered restructuring on July 22, following missed milestone payments expected from Unither Pharmaceuticals.
- Insolvency administrator Dr. Ulla Reisch moved to close operations; the court accepted the motion and ordered the business closure.
- Asset sales are set to begin under the insolvency process, according to the research update.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
